



Contents lists available at ScienceDirect

Matrix Biology

journal homepage: www.elsevier.com/locate/matbio

Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47

Elfaridah P. Frazier^a, Jeff S. Isenberg^b, Sruti Shiva^c, Lei Zhao^a, Paul Schlesinger^a, Julie Dimitry^a, Mones S. Abu-Asab^d, Maria Tsokos^d, David D. Roberts^d, William A. Frazier^{a,*}

^a Departments of Biochemistry and Molecular Biophysics, Cell Biology and Physiology, Washington University School of Medicine, St. Louis MO 63110, United States

^b Department of Medicine, Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States

^c Departments of Pharmacology and Chemical Biology, Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States

^d Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States

ARTICLE INFO

Article history:

Received 4 November 2010

Received in revised form 15 December 2010

Accepted 16 December 2010

Available online xxxx

Keywords:

Mitochondrial biogenesis

Skeletal muscles

Mitochondria

CD47 receptor

Fast twitch fibers

Slow-twitch fibers

ABSTRACT

CD47, a receptor for thrombospondin-1, limits two important regulatory axes: nitric oxide-cGMP signaling and cAMP signaling, both of which can promote mitochondrial biogenesis. Electron microscopy revealed increased mitochondrial densities in skeletal muscle from both CD47 null and thrombospondin-1 null mice. We further assessed the mitochondria status of CD47-null vs WT mice. Quantitative RT-PCR of RNA extracted from tissues of 3 month old mice revealed dramatically elevated expression of mRNAs encoding mitochondrial proteins and PGC-1 α in both fast and slow-twitch skeletal muscle from CD47-null mice, but modest to no elevation in other tissues. These observations were confirmed by Western blotting of mitochondrial proteins. Relative amounts of electron transport enzymes and ATP/O₂ ratios of isolated mitochondria were not different between mitochondria from CD47-null and WT cells. Young CD47-null mice displayed enhanced treadmill endurance relative to WT and CD47-null gastrocnemius had undergone fiber type switching to a slow-twitch pattern of myoglobin and myosin heavy chain expression. In 12 month old mice, both skeletal muscle mitochondrial volume density and endurance had decreased to wild type levels. Expression of myosin heavy chain isoforms and myoglobin also reverted to a fast twitch pattern in gastrocnemius. Both CD47 and TSP1 null mice are leaner than WTs, use less oxygen and produce less heat than WT mice. CD47-null cells produce substantially less reactive oxygen species than WT cells. These data indicate that loss of signaling from the TSP1-CD47 system promotes accumulation of normally functioning mitochondria in a tissue-specific and age-dependent fashion leading to enhanced physical performance, lower reactive oxygen species production and more efficient metabolism.

© 2011 Published by Elsevier B.V.

1. Introduction

Mitochondrial biogenesis is regulated by many factors including developmental cues, energy demand, thermal stress, exercise, fasting and hormonal regulators (Lin et al., 2005; Feige and Auwerx, 2007; Leone et al., 2005; Benton et al., 2008). These diverse signals converge on the transcriptional coactivators peroxisome proliferator-activated receptor γ coactivator-1 α and β (PGC-1 α/β). These two coactivators have distinct but overlapping tissue expression and regulatory properties and are themselves regulated at the level of transcription (Lai et al., 2008; Uldry et al., 2006). PGC-1 α acts with PPARs (peroxisome proliferator-activating receptors), ERRs (estrogen-related receptors) and NRF-1 (nuclear respiratory factor-1) to coordinate

mitochondrial biogenesis and energy metabolism (Finck and Kelly, 2007). Sirt-1, a member of the family of sirtuin deacetylases, thought to have a causal role in longevity due to caloric restriction, has been reported to act upon PGC-1 α , deacetylating it and thus facilitating its interaction with NRF-1 to promote mitochondrial biogenesis (Nemoto et al., 2005; Feige and Auwerx, 2008). Calorie restricted mice (Lopez-Lluch et al., 2006), Sirt-1 over-expressing transgenics (Bordone et al., 2007) and mice treated with resveratrol (Lagouge et al., 2006) or its analogs (Feige et al., 2008) have more mitochondria than control mice. Thus, the notion arises that increasing or maintaining mitochondrial biogenesis opposes metabolic syndrome and benefits cardiovascular function and perhaps longevity (Guarente, 2008).

On a molecular level, cyclic AMP is a major activator, via CREB, of the transcription of PGC1 α (Wu et al., 2006) and of genes encoding mitochondrial proteins (Carlezon et al., 2005). It has also been reported that cGMP, synthesized by soluble guanylyl cyclase in response to nitric oxide (NO) stimulation, can activate PGC1 α expression (Lira et al.-a,b; Nisoli and Carruba, 2006). Therefore,

* Corresponding author at: Department of Biochemistry and Molecular Biophysics, 8231, Washington University School of Medicine, 660 South Euclid Ave, St. Louis, MO 63110, United States. Tel.: +1 314 362 3348; fax: +1 314 362 7183.

E-mail address: frazier@wustl.edu (W.A. Frazier).

pathways that increase both cGMP and cAMP can potentially stimulate mitochondrial biogenesis.

Recently, we discovered that thrombospondin-1 (TSP1) and its receptor CD47 constitute a previously unknown regulatory system that limits the action of NO in all vascular cell types and several tissues (Isenberg et al. (2006a, 2008f)). TSP1 ligation of CD47 blocks the canonical NO signaling pathway at three points: activation of eNOS is inhibited (Bauer et al.), NO stimulation of soluble guanylyl cyclase is impaired (Miller et al.) and stimulation of protein kinase G by cGMP and its analogs is also blunted (Isenberg et al., 2008g). Furthermore, engaging CD47 with TSP1 or TSP1-mimetic antibodies to CD47 results in a dramatic suppression of cellular cAMP levels (Frazier et al., 1999; Wang et al., 1999; Manna and Frazier, 2003; Yao et al., in press). The physiological relevance of this CD47 suppression of cAMP and cGMP is confirmed by the observation that levels of both cyclic nucleotides are elevated in tissues of CD47 null mice (Isenberg et al., 2009; Yao et al., in press). Thus CD47 blunts signaling emanating from both cGMP and cAMP pathways and therefore could potentially limit mitochondrial biogenesis. Since CD47 is widely, if not ubiquitously expressed in mammalian tissues, such an effect might have a significant impact on mitochondrial numbers in many tissues and organs.

To investigate this issue, we have characterized the mitochondrial status of TSP1 and CD47 knockout mice and report here that young mice lacking either TSP1 or CD47 have a greater mitochondrial volume/mass than WT and this effect is most prominent in skeletal muscle, resulting in muscle fiber type switching and greater endurance relative to WT mice. As WT mice age, skeletal muscle mitochondrial numbers and performance decrease. By ca. one year of age, both TSP1 null and CD47 null mice have lost their increased muscle mitochondrial load, their endurance advantage over WT mice and their enhanced metabolic efficiency. However, aging CD47 and TSP1 nulls remain leaner than matched WT. Thus TSP1–CD47 signaling limits mitochondrial biogenesis in young skeletal muscle and CD47 knockout has a substantial, but transient impact on muscle physiology.

2. Results

2.1. Mitochondrial mRNAs are elevated in skeletal muscle of young CD47 null mice

Both cGMP (stimulated by NO) and cAMP (acting via CREB) have been reported to increase mitochondrial biogenesis. TSP1–CD47 signaling can lower cellular levels of both cyclic nucleotides (Frazier et al., 1999; Isenberg et al., 2006b), and both TSP1- and CD47-null mice have elevated levels of cGMP and cAMP in tissues. While TSP1 can bind many receptors, the modulation of cyclic nucleotide levels by TSP1 is mediated via CD47 (Chung et al., 1999; Isenberg et al., 2008b). Therefore we hypothesized that CD47-null mice might have more mitochondria than matched WT. Quantitative RT-PCR (Q-PCR) of certain “marker mRNAs” is a sensitive way to rapidly survey tissues for their content of mitochondria (Lagouge et al., 2006; Feige and Auwerx, 2007). Here we surveyed the mRNA levels of cytochrome *b* (encoded by mitochondrial DNA), cytochrome *c*, PGC-1 α and NRF-1 (all encoded by nuclear DNA) as indicators of the mitochondrial content and ongoing biogenesis in tissues of 3 month old CD47-null mice. As seen in Fig. 1, levels of the mitochondrial marker mRNAs were not significantly elevated relative to WT in most tissues. However, skeletal muscle (soleus and gastrocnemius) exhibited 3- to 5-fold higher expression of all four markers relative to WT tissues from littermates. CD47 is also well expressed in skeletal muscle of WT mice (determined by Q-PCR, not shown). To verify the Q-PCR results at the protein level, we also performed Western blotting of WT and CD47-null tissue lysates from gastrocnemius and, for comparison, from heart ventricle tissue. As shown in Supplemental Fig. S1, skeletal muscle from CD47-null animals had substantially greater concentra-




Fig. 1. Tissue survey of mitochondrial mRNA expression. RNA was prepared from the indicated tissues with the RNA Later^c method and levels of mRNA for cytochrome *c* (cyt *c*), cytochrome *b* (cyt *b*), nuclear respiratory factor-1 (NRF-1) and PGC1 α were determined by Q-PCR using the Sybr Green method. Data is plotted as the ratio of the CD47-null value to the WT value, both of which were first normalized to the level of mRNA for the ribosomal protein 36B4. Tissue from 5 to 16 mice was processed independently for each value shown.

tions of cytochrome *c* (a soluble mitochondrial protein) and VDAC1 (a mitochondrial membrane protein) in agreement with the Q-PCR results in Fig. 1. In contrast, WT and CD47-null hearts (ventricle) of 3 month old mice had comparable levels of both mitochondrial proteins (Fig. S1). Based on this data and the fact that skeletal muscle represents the largest depot of mitochondrial mass in the body, we elected to examine in detail the mitochondrial phenotype of skeletal muscle from the CD47-null mice.

2.2. CD47 and TSP1 null skeletal muscle contain more mitochondria than WT muscle

Skeletal muscle from WT and CD47 nulls was examined with thin section transmission electron microscopy. The WT muscles showed the stereotypical pattern of myofibrillar bands with long rows of usually single intermyofibrillar mitochondria aligned between myofibrils (Fig. 2A). In clear contrast, CD47-null soleus (Fig. 2B) contained a higher density of mitochondria than its WT counterpart. Mitochondrial volume density calculations indicate nearly a two-fold increase in the volume of mitochondria in CD47-null soleus: wt soleus 6.8% ($\pm 0.6\%$, sem) vs CD47-null soleus 11.3% ($\pm 1.5\%$, sem) ($p < 0.05$) mitochondrial area per field (Fig. 2C). In addition, the mitochondria in the CD47-null muscle were of a much broader range of sizes than WT




Fig. 2. Electron microscopy of soleus muscle from CD47-null and WT mice. Soleus was rapidly harvested and fixed in a mixture of paraformaldehyde and glutaraldehyde and prepared for thin section TEM. WT muscle is shown in A and CD47-null in B. White arrows indicate mitochondria. The final magnification is 10,000 \times for both. In C, percent mitochondrial area in ten randomly selected fields was measured for each of 3 animals for each genotype. The CD47 null data (top panel) is for soleus, a type I slow-twitch muscle and the TSP1 null data (bottom panel) is for gastrocnemius, a type II fast twitch muscle. Comparable increases were seen in both muscle types in both knockouts.

163 with many very large mitochondria present (Fig. 2A and B). Clusters of
 164 subsarcolemmal mitochondria were observed in both WT and
 165 knockout soleus, and these were included in the overall quantification
 166 process above. Like the intermyofibrillar mitochondria, the subsarco-
 167 lemmal mitochondria in CD47-null soleus also had a much wider size
 168 variation than those in WT soleus. Similar increases in mitochondrial
 169 density and volume were observed in gastrocnemius muscle
 170 harvested from 3 month old TSP1 null mice relative to WT (Fig. 2C,
 171 Fig. S2). TSP1 null gastrocnemius had 70% more mitochondria, and the
 172 mitochondrial volume was two-fold greater than WT (Fig. 2C). As in
 173 the CD47 null muscle, there was an increase in the size heterogeneity
 174 of mitochondria in the TSP1 nulls (Fig. S2).

175 In contrast to soleus muscle, electron microscopy of heart
 176 papillary muscle from the same mice did not reveal any difference
 177 in mitochondrial density (WT 27.2% \pm \pm 0.1, sem, CD47-nulls
 178 27.4% \pm \pm 0.8) sem) or appearance between CD47-nulls and WTs.
 179 Enzymatic assays of complexes I, II and IV activities (normalized to
 180 citrate synthase activity) revealed no significant differences be-
 181 tween WT and CD47-null mitochondria from skeletal muscle or liver
 182 (Fig. S3). Further, the ATP/O₂ ratio of mitochondria isolated from
 183 gastrocnemius was not different for CD47-null and WT mice (not
 184 shown). Thus, the increased numbers of mitochondria in CD47-null
 185 skeletal muscle appear to function normally.

186 2.3. Age-dependent changes in skeletal muscle mitochondria in CD47- 187 null mice

188 To determine if the dramatic increase in mitochondria in CD47-
 189 null skeletal muscle is maintained as the mice age, we determined
 190 the expression of mitochondrial genes (as in Fig. 1) in skeletal
 191 muscle obtained from 12 month old CD47-null mice. To our
 192 surprise, expression of these genes had decreased to WT levels
 193 (which themselves had fallen with age) by 12 months of age (Fig. 3).
 194 Mitochondrial content (volume density) in soleus muscle of
 195 12 month old mice was analyzed by quantifying EM images as
 196 above. In agreement with the Q-PCR results, the volume density of
 197 mitochondria was not significantly different between CD47 null and
 198 WT soleus at 12 months of age (CD47-null 6.89 \pm 0.30 vs WT 8.86 \pm
 199 0.65).

200 2.4. Functional consequences of age-dependent alterations in 201 mitochondrial content

202 Endurance training and dietary or genetic manipulations that
 203 enhance mitochondrial biogenesis in skeletal muscle often result in
 204 increased running endurance (Feige et al., 2008; Lagouge et al., 2006).
 205 CD47-null and WT mice (ages 3 and 12 months) were tested in a
 206 standard treadmill running protocol. As reported for 3 month old
 207 TSP1-null mice (Malek and Olfert, 2009), we found that the young
 208 CD47-null mice were able to run nearly twice as long as matched WT
 209 controls before becoming exhausted (Fig. 4A). By 12 months of age,
 210 the running endurance of WT mice had declined to nearly half that of
 211 their younger counterparts, an expected result (Fig. 4A). The running
 212 endurance of the 12 month old CD47 nulls also decreased and was no
 213 longer significantly different than that of the 12 month old WT mice
 214 (Fig. 4A). A similar decrease in endurance was found in the older TSP1
 215 null mice (not shown).

216 With exercise training, normally fast twitch glycolytic muscle
 217 fibers (type II) can switch their phenotype to slow-twitch, mitochon-
 218 dria-rich fibers (type I) (Booth et al., 2002; Holloszy, 2008;
 219 Spangenburg and Booth, 2003). Forcing increased mitochondrial
 220 biogenesis in skeletal muscle can also convert fast twitch fibers to the




Fig. 3. Age-dependent decrease in expression of mitochondrial marker RNAs in CD47 null mice. RNA prepared as in Fig. 1 was amplified using the Sybr Green method. Data is normalized to values for 36B4 mRNA and expressed as the ratio of CD47 null to WT values. At 12 months of age, values for all three RNAs were the same in CD47 null and WT muscle.




Fig. 4. Young CD47-null mice have improved endurance and muscle fiber type switching. (A) Running endurance of 3 month old CD47-nulls is significantly superior to WT (n = 7–8). (B) CD47-null gastrocnemius muscle, normally a fast twitch muscle, expresses high levels of markers of slow-twitch, mitochondria-rich fibers compared to WT. Q-PCR data expressed as the ratio of CD47-null to WT value for each mRNA as in Fig. 1 (n = 8).

slow-twitch phenotype (Lagouge et al., 2006). As skeletal muscle transitions from fast to slow twitch, expression of myosin heavy chain isoforms shifts from form 2B to 2X, 2A and finally to form 1. As seen in Fig. 4B, gastrocnemius (normally a fast twitch muscle) from 3 month old CD47-nulls had a myosin HC isotype expression profile much more characteristic of slow-twitch fibers with MHC isoform 1 being 23.9 ± 12.7 fold over-expressed relative to WT. Myoglobin, another protein enriched in slow-twitch muscle, was 40.9 ± 26.5 fold over-expressed in CD47-null muscle (both MHC-1 and myoglobin expression were significantly greater in CD47-null muscle).

2.5. Age-dependent changes in indicators of metabolic efficiency

Accumulation of body fat and increasing weight are hallmarks of aging in mice. At three months of age, CD47-null mice weigh slightly but significantly less than WT (Fig. 5A). Male and female WT mice weighed the same at this age as did male and female CD47 nulls. Identical data was obtained for the 3 month old TSP1 nulls (not shown). The body composition of the CD47 null mice was analyzed with DEXA, revealing that they did in fact have significantly less body fat than WT mice (Fig. 5C). With increasing age, both WT mice and TSP1 and CD47 nulls gained weight, but the weight of both nulls remained significantly lower than WT over the same interval (Fig. 5A). Thus lack of TSP1 or CD47 limits the age-dependent increase in adiposity normally seen in WT mice.

2.6. CD47-null cells generate less ROS than WT cells

Mitochondria are the major cellular source of reactive oxygen species (ROS). We, therefore, determined the ROS production of mitochondria in CD47-null and WT cells using fluorescent indicators of superoxide (dihydroethidium and Mitosox^c) and other ROS species (dichlorofluorescein). For this study we turned to primary aortic smooth muscle cells (SMC) isolated from male 6 week old CD47-null




Fig. 5. Body composition of CD47 null and WT mice. (A) CD47-null mice weigh significantly less than WT at both 3 and 12 months of age. Lean (B) and fat (C) body mass were determined by DEXA at both ages. CD47-nulls have significantly less body fat than WT, accounting for the difference in total body weight (n = 4–6).

and WT mice. The cells were incubated with the indicator compounds and the rate of increase in fluorescence (slope) was normalized to the fluorescence of DAPI as an index of cell number. As detected with Q-PCR and confirmed by Western blotting, the CD47-null aorta, which is composed largely of SMC, also had elevated levels of mitochondrial markers but to a lesser extent than skeletal muscle. However, as seen in Fig. 6, all three reporters indicated a marked reduction in the levels of total cellular superoxide (dihydroethidium), mitochondrial superoxide (Mitosox^c) and total ROS (DCF) generation by the CD47-null cells. Therefore, the production of ROS per mitochondrion is very low in the absence of CD47, suggesting that these mitochondria are very efficient. Production of ROS by isolated skeletal muscle mitochondria




Fig. 6. CD47-null aortic smooth muscle cells produce much less ROS than WT. Early passage aortic smooth muscle cells from male 6 week old null (solid bar) and WT mice (empty bar) were seeded on black 96 well tissue culture plates, grown to confluence, then treated with dihydroethidium which reacts with superoxide to produce fluorescent ethidium (HE), dichlorofluorescein (DCF) which becomes fluorescent after reaction with several types of ROS or Mitosox which detects primarily mitochondrial superoxide. The increase of fluorescence over time (slope) was normalized to cell number determined as the DAPI (nuclear) fluorescence of the same cells. The figure is representative of 3 separate experiments with different batches of cells. Aortic smooth muscle cells were isolated from 6–8 weeks old mice.

in the presence of glutamate (a complex I substrate) was also monitored with the DCF oxidation assay. The rate of DCF oxidation by mitochondria from CD47 null skeletal muscle was not significantly different than that of mitochondria from WT muscle (not shown). Therefore, it is the cellular context in which the mitochondria find themselves that appears to determine their rate of ROS production. In support of this notion, Oxymax respirometry of unstressed 3 month old mice (for a 24 h period) indicated that both CD47 null and TSP1 null mice use less oxygen than WT mice (Fig. S3). Further, production of heat by both knockout mouse strains was lower than that of WT controls (not shown). RER (respiratory exchange ratio), an index of mitochondrial substrate utilization, was significantly elevated in both TSP1 and CD47 null young mice compared to WT littermate controls. Interestingly, all three parameters, oxygen consumption, heat production and RER had returned to WT control levels in the older TSP1 and CD47 null mice. Therefore, mitochondrial density, endurance and cellular and systemic indicators of mitochondrial function all follow the same age-dependent course in TSP1 and CD47 null mice.

2.7. Discussion

Mitochondrial biogenesis is regulated in a tissue-specific manner to meet the changing demands of physical activity, dietary energy sources and metabolic and environmental stresses. From aging studies, the concept has arisen that increasing or maintaining mitochondrial numbers and function could be important for extending lifespan or healthspan (Guarente, 2008; Katic et al., 2007; Lopez-Lluch et al., 2006). Many of the signals that affect mitochondrial numbers impinge on the transcriptional coactivator PGC-1 α , which acts in concert with NRF-1 to coordinate transcription of the many genes, both nuclear and mitochondrial, that are required to build a functional mitochondrion. PGC1 α itself is activated by sirtuin-1 deacetylation, which is thought to promote healthy aging and increased mitochondrial biogenesis (Nemoto et al., 2005; Salminen and Kaarniranta, 2009). We found that skeletal muscle in young (3 month old) CD47 null and TSP1 null mice has a dramatically increased complement of mitochondria. Expression of cytochromes *b* and *c* as well as PGC1 α and NRF-1 is significantly elevated in CD47 null skeletal muscle relative to WT levels (Fig. 1). While some other CD47-null tissues sampled (Fig. 1) trended toward higher levels of mitochondrial marker expression than WT, none reached significance. Therefore, the effect of the CD47 knockout to increase mitochondrial numbers appears to be most evident in skeletal muscle. EM analysis of

skeletal muscle revealed that the increased numbers of mitochondria appear ultrastructurally normal with the proper electron density and arrangement of cristae (Fig. 2). However, mitochondria in CD47 and TSP1 null muscle exhibit a much wider range of sizes and shapes, perhaps reflecting the role of cAMP-dependent phosphorylation in regulating mitochondrial fission/fusion, i.e., the increased level of cAMP may shift the balance of fission/fusion toward net fusion resulting in larger mitochondria (Chang and Blackstone, 2007; Cribbs and Strack, 2007). Nonetheless, the mitochondria isolated from CD47 null muscle appear to function normally in terms of ATP production and the activity of the electron transport chain enzymes. It is presumably this increased load of functional mitochondria along with the switch to type II fibers that confers a significant endurance benefit on the young CD47 null mice. The similar increase in mitochondria in both the CD47 and TSP1 null mice further reinforces the ligand–receptor relationship of TSP1 and CD47 as seen in numerous studies comparing the phenotypes of these two knockouts (Isenberg et al., 2007a,b, 2008a,c; Maxhimer et al., 2009).

Additional phenotypic alterations in the CD47 null mice may also be related to the early abundance of PGC1 α . Interestingly, many phenotypes of the young CD47-null mice closely resemble those of transgenic mice expressing PGC-1 α under control of the muscle creatine kinase promoter, which drives expression of PGC-1 α in all skeletal muscle at levels 5 to 6 times that in normal fast twitch muscle. This level of PGC1 α is similar to the levels seen in type I slow-twitch muscle fibers such as soleus (Lin et al., 2002) (Wenz et al., 2009). In our study, we found a ca. 4-fold increase in PGC1 α expression in CD47 null skeletal muscle (Fig. 1). The muscles of the PGC1 α transgenic mice that are normally high in type II fibers, e.g. quadriceps, gastrocnemius and others, have more mitochondria and display fiber type switching which contributes to their better endurance just as seen here with the CD47-null mice (Fig. 4). Additional similarities between young CD47-nulls and the PGC1 α transgenics (Wenz et al., 2009) include lower weight and less body fat than WT, lower ROS production, increased sirtuin-1 expression (our unpublished data), increased bone mineral density (Uluckan et al., 2009) and increased muscle vascularization (Isenberg et al., 2007c; Malek and Olfert, 2009).

Since CD47 suppresses both cGMP and cAMP levels and both cyclic nucleotides have been reported to stimulate mitochondrial biogenesis, our hypothesis on beginning this study was that CD47-null mice might have greater numbers of mitochondria in many tissues. However, the dramatic increase in mitochondria limited largely to skeletal muscle in the CD47 knockouts was unexpected. It is interesting that eNOS-null mice have decreased numbers/mass of mitochondria and this deficit is most prominent in skeletal muscle (Le Gouill et al., 2007). Thus the mirror image effects of CD47 and eNOS knockout are consistent with the notion that lack of CD47 increases NO signaling (Isenberg et al., 2008b) which is at least partially responsible for the increase in mitochondria (Lira et al.-a,b). The eNOS-deficient muscles had fewer and smaller mitochondria than WT, and the mitochondria were somewhat defective in function (Nisoli et al., 2004; Le Gouill et al., 2007). Conversely, mitochondria in the CD47 nulls seem to be more efficient than WT in terms of their lower production of ROS and the lower oxygen utilization of the mice. As in the case of exercise (Lira et al.-a,b), caloric restriction (Lopez-Lluch et al., 2006), resveratrol treatment (Lagouge et al., 2006), Sirt1 (Bordone et al., 2007) and PGC-1 α over-expression (Wenz et al., 2009), the fiber type of fast twitch, type II gastrocnemius muscle in the CD47 nulls showed a pronounced shift to a myoglobin and MHC expression pattern characteristic of slow-twitch, type I, mitochondria-rich muscle. The functional correlate of this switch is seen in the nearly two-fold increase in treadmill time of the CD47-nulls vs WT mice. Therefore, the increase in skeletal muscle mitochondria in the young CD47-nulls and their decrease in the eNOS-nulls may reflect an important and specific role for NO in the regulation of skeletal muscle mitochondria numbers and function.

Perhaps the most striking feature of the mitochondrial phenotype of the CD47-null mice is that the differences with WTs seen at three months of age are almost completely gone by one year of age. The decrease in mitochondria density with age occurs in WT animals under normal conditions. Both density and number of mitochondria in quadriceps muscle of WT mice decreased 3-fold between the ages of 2 and 11 months (Corsetti et al., 2008), a time frame comparable to that studied here. In addition the data for WT controls in the PGC1 α transgene study evidenced the same age-dependent decline in all functional parameters from 3 to 12 months of age (Wenz et al., 2009). In that study, the continued elevated expression of PGC1 α in muscle prevented or slowed much of the age-dependent decrement in mitochondria and muscle performance and other sequelae of aging. In our case, there is a marked decline in mitochondrial transcriptional regulators and the density of mitochondria in the CD47 null mice by one year of age. The functional decline in muscle performance with age is characteristic of sarcopenia, a severe problem for our aging population. It is likely that the effect we observe in the CD47 nulls is due to a more robust biogenesis of mitochondria in young animals that then follows the normal path of decline with age. Consistent with this idea is the elevated expression of PGC1 α and NRF1, components that regulate mitochondrial biogenesis, in the young CD47 nulls. The factors that govern the rapid, age-dependent decline in mitochondrial density and muscle function are not yet known. However, it is intriguing to note that expression levels of sirt-1, which deacetylates and activates PGC1 α (Rodgers et al., 2005), also drop substantially in skeletal muscle between 3 and 12 months of age (our unpublished data).

In other studies, deletion of either TSP1 or CD47, knockdown of CD47 expression and even blockade of CD47 with antibodies resulted in improved healing of ischemic skin flaps (Isenberg et al., 2007a) and skin grafts (Isenberg et al., 2008e), less damage in ischemia-reperfusion injury models (Isenberg et al., 2008d), reduced stroke damage (Jin et al., 2009) improved vasodilation and cardiac function (Isenberg et al., 2008a) and even protection from ionizing radiation (Isenberg et al., 2008c). A common aspect of many of these models is the generation of ROS. We have seen here that CD47 null cells generate less mitochondrial ROS. Since deletion of either TSP1 or CD47 results in what appears to be a “healthier” or more robust phenotype, we must wonder just what the physiological role of the TSP1–CD47 system might be with regard to mitochondrial homeostasis. It has become clear in recent years that both the content and form of mitochondria are very dynamic, responding rapidly to changes in diet, temperature, hormonal status and likely yet unknown additional factors. The steady state content of mitochondria depends on the balance of biogenesis and removal by autophagy, the preferred mode of disposal and recycling of mitochondria (Scherz-Shouval et al., 2007). Recent literature indicates that autophagy itself is highly regulated and is a necessary process to avoid the accumulation of damaged mitochondria (Scherz-Shouval and Elazar, 2007). This is particularly true in postmitotic tissues such as brain and cardiac muscle. Skeletal muscle is able to regenerate to some extent, calling on a pool of muscle stem cells called satellite cells that exist within muscle fibers, a process that is also sensitive to NO levels (Wozniak and Anderson, 2007). Our finding that the TSP1–CD47 system seems to limit the mitochondrial content of skeletal muscle, at least in young mice, could be due to suppression of mitochondrial biogenesis and/or stimulation of mitochondrial turnover. Further studies will be necessary to determine the mechanism of these effects.

We have shown here for the first time, that lack of CD47 or its ligand, TSP1, causes an increase in mitochondrial density in skeletal muscle, leading to a performance benefit and increased metabolic efficiency. Mitochondria in tissues of the CD47-null mice are more efficient, producing lower levels of ROS, thus reducing the deleterious effects of oxidative damage. The TSP1 and CD47 null mice are also leaner than WTs, suggesting that the enhanced mitochondrial density

along with less ROS production may lead to benefits similar to those obtained via caloric restriction and sirtuin-1 or AMP kinase activation. Indeed, the phenotypes of the CD47-null mice are concordant in many respects with those of calorie-restricted mice. Not only does the TSP1–CD47 system limit cardiovascular health (Isenberg et al., 2008f), but it also exacerbates diseases of the aging cardiovascular system (Isenberg et al., 2007b) and may even limit lifespan and/or healthspan. Testing these ideas will require long-term aging studies that may also reveal new aspects of the physiology of the CD47 null and TSP1 null mice.

3. Materials and methods

3.1. Mice

Wild type and CD47-null C57Bl/6J mice were produced by breeding heterozygotes. The CD47-null line (Lindberg et al., 1996) has been backcrossed to the C57Bl/6J JAX parental strain over 30 times. All mice were genotyped by assessing CD47 expression on red blood cells by flow cytometry and/or by PCR. TSP1 null mice were bred in a pure C57Bl/6J background and periodically backcrossed with WTs to minimize genetic drift. Mice were maintained on *ad lib* chow and water. Genotype was confirmed by PCR. For tissue collection, anesthetized mice were sacrificed by cervical dislocation. Treadmill testing (run to exhaustion) was performed as described (Lagouge et al., 2006). Body fat and lean weight of mice were determined by Dual Energy X-ray Absorptometry (DEXA) in a PIXImus2 scanner according to the manufacturer's protocol (Lunar Corp., Madison, WI). All animal procedures were approved by the NIH or Washington University Committees on Animal Studies.

3.2. Real-time quantitative PCR (Q-PCR)

Tissues were harvested and placed directly in RNeasy lysis buffer (Ambion, Applied Biosystems, Foster City, CA) and stored at -80°C for experiments. A 50–100 mg sample of tissue was homogenized in 1 ml of Trizol (Invitrogen, Carlsbad, CA). Total RNA was isolated according to the manufacturer's protocol, using a high salt solution (0.8 M sodium citrate, 1.2 M NaCl) to yield optimum RNA precipitation. RNA concentrations were determined spectrophotometrically with a Nanodrop spectrophotometer (NanoDrop Technology, Inc., Wilmington, DE). Prior to cDNA synthesis, 1 μg of RNA was treated with 1 μl DNase I, Amp Grade (Invitrogen, Carlsbad CA) to prevent genomic DNA contamination. cDNA was then synthesized according to the manufacturer's protocol using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA) and diluted 1:10. Oligonucleotide primers (Supplemental Table 1) for mitochondrial genes (Duncan et al., 2007), PGC1 α , myoglobin and myosin heavy chain isoforms (Oh et al., 2005) were acquired from Integrated DNA Technologies (Coralville, IA). Constitutively expressed GAPDH and 36B4 ribosomal protein were selected as endogenous controls to correct for any variation in RNA loading. A total reaction mixture of 25 μl consisted of diluted cDNA, 1 \times iQ Sybr Green Supermix (Bio-Rad, Richmond CA), 200 nM forward and reverse primers. Relative quantification of mRNA was performed using the following thermal protocol: 95 $^{\circ}\text{C}$ for 3 min, 40 cycles at 95 $^{\circ}\text{C}$ for 15 s followed by 55 $^{\circ}\text{C}$ for 40 s for annealing and extension using an ABI 7000 thermal cycler (Applied Biosystems, Foster City, CA). The mRNA expression of gene of interest from CD47-null tissues was expressed relative to the expression of the gene in WTs, which was arbitrarily set to 1.

3.3. Western blot analysis

Gastrocnemius and heart ventricles obtained from WT and CD47-null mice and stored in RNeasy lysis buffer at -80°C were thawed at room temperature and minced. Tissue fragments were transferred to a 0.5 ml centrifugal filter device with a 0.45 μm filter (Amicon, 494

495 Millipore, Bedford, MA). RNAlater crystals embedded in the tissue
 496 were extracted 4–5 times with 80% acetonitrile (Sigma, St. Louis, MO)
 497 which was removed by centrifugation at 14,000 rpm for 30 s. Pellets
 498 were then collected and protein was extracted using RIPA buffer plus
 499 a protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN) at
 500 37 °C for 1 h. A 20 µg protein sample from each tissue was run on a
 501 4–20% gradient Tris–HCl precast gel (Biorad). Primary antibodies
 502 were against cytochrome c (Santa Cruz Biotechnology, Santa Cruz, CA)
 503 and VDAC (Novus Biological, Littleton, CO); identical protein loading
 504 was determined by pre-staining with Coomassie blue.

505 3.4. Determination of reactive oxygen species

506 Primary cultures of aortic smooth muscle cells were established as
 507 described (Isenberg et al., 2005). Cells from WT and CD47-null mice
 508 were matched for sex, age of mice and number of passages in culture
 509 (less than 4). Cells cultured in black 96 well plates were shifted to 2%
 510 serum for 48 h, and then incubated with DCF (2,7-dichlorofluorescein,
 511 Sigma, St. Louis MO), dihydroethidine, or MitoSox (Invitrogen,
 512 Carlsbad, CA) in HEPES buffered saline, pH 7.2 at 37 °C in a BioTek
 513 (Winooski, VT) fluorescence plate reader in the kinetic mode with
 514 readings every 10 min for 2 to 4 h. Cells were fixed in 1% formalin for
 515 15 min and stained with DAPI (Invitrogen) to determine cell numbers
 516 with the plate reader.

517 3.5. Electron microscopy

518 Tissue for electron microscopy was harvested rapidly and placed in
 519 a glutaraldehyde/paraformaldehyde fixative. Embedding sectioning
 520 and staining were carried out as described (Schmidt et al., 2009;
 521 Timmers et al., 2008). Ultrathin sections (90 nm) were made and
 522 double stained with uranyl acetate and lead citrate, and viewed in a
 523 Philips CM10 transmission instrument. Images for analysis were taken
 524 at a magnification of 10,000×. The microscopist, (blinded to sample
 525 genotype) randomly selected 10 fields (CD47 nulls) or 30 fields (TSP1
 526 nulls) per grid to photograph. Tissues from three different mice were
 527 analyzed with at least three sections obtained from each mouse.
 528 Mitochondria number and volume density were analyzed using Image
 529 J or Image-Pro Plus version 6.2.

530 3.6. Characterization of mitochondria ex vivo

531 Mitochondria isolated from skeletal leg muscles were assayed for
 532 activity of electron transport enzymes as described (Shiva et al.,
 533 2007). Determination of the rate of oxygen utilization by isolated
 534 mitochondria was performed using a Clark electrode. Isolated
 535 mitochondria were also tested for the production of ROS by oxidation
 536 of DCF with glutamate as substrate in the fluorescence plate reader in
 537 the kinetic mode.

538 3.7. Statistical analyses

539 All statistical analyses were performed using Prism (GraphPad
 540 Software, San Diego, CA). All data are expressed as mean ± SEM of n
 541 experiments. The primary comparison was made between matched
 542 littermate WT and CD47-null mice. Statistical significance between
 543 WT and CD47-null values were assessed with the unpaired t-test, a
 544 P<0.05 was considered statistically significant.

545 Supplementary materials related to this article can be found online
 546 at doi:10.1016/j.matbio.2010.12.004.

547 Acknowledgements

548 We thank Dr. Robert Schmidt, Director of the Electron Microscopy
 549 Core (Washington University School of Medicine) for helpful advice.
 550 Drs. Daniel Kelly, Jennifer Duncan, John Lehman, Pamela Manning and

John Holloszy, all of Washington University School of Medicine, also
 provided advice.

Funding was provided by R01 HL054390 from the NHLBI to WAF, 553
 the Intramural Research Program of the NIH, NCI, Center for Cancer 554
 Research to DDR and MT, and K22 CA128616 to JSI. EPF is a 555
 postdoctoral fellow of the American Heart Association. 556

References 557

- Bauer, E.M., Qin, Y., Miller, T.W., Bandle, R.W., Csanyi, G., Pagano, P.J., Bauer, P.M., 558
 Schnermann, J., Roberts, D.D., and Isenberg, J.S. Thrombospondin-1 supports blood 559
 pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. 560
 Cardiovasc. Res. 561
- Benton, C.R., Wright, D.C., Bonen, A., 2008. PGC-1alpha-mediated regulation of gene 562
 expression and metabolism: implications for nutrition and exercise prescriptions. 563
 Appl. Physiol. Nutr. Metab. 33, 843–862. 564
- Booth, F.W., Chakravarthy, M.V., Spangenburg, E.E., 2002. Exercise and gene expression: 565
 physiological regulation of the human genome through physical activity. J. Physiol. 566
 543, 399–411. 567
- Bordone, L., Cohen, D., Robinson, A., Motta, M.C., van Veen, E., Czopik, A., Steele, A.D., 568
 Crowe, H., Marmor, S., Luo, J., et al., 2007. SIRT1 transgenic mice show phenotypes 569
 resembling calorie restriction. Aging Cell 6, 759–767. 570
- Carlezon Jr., W.A., Duman, R.S., Nestler, E.J., 2005. The many faces of CREB. Trends 571
 Neurosci. 28, 436–445. 572
- Chang, C.R., Blackstone, C., 2007. Cyclic AMP-dependent protein kinase phosphorylation 573
 of Drp1 regulates its GTPase activity and mitochondrial morphology. J. Biol. 574
 Chem. 282, 21583–21587. 575
- Chung, J., Wang, X.Q., Lindberg, F.P., Frazier, W.A., 1999. Thrombospondin-1 acts via 576
 IAP/CD47 to synergize with collagen in alpha2beta1-mediated platelet activation. 577
 Blood 94, 642–648. 578
- Corsetti, G., Pasini, E., D'Antona, G., Nisoli, E., Flati, V., Assanelli, D., Dioguardi, F.S., 579
 Bianchi, R., 2008. Morphometric changes induced by amino acid supplementation in 580
 skeletal and cardiac muscles of old mice. Am. J. Cardiol. 101, 26E–34E. 581
- Cribbs, J.T., Strack, S., 2007. Reversible phosphorylation of Drp1 by cyclic AMP- 582
 dependent protein kinase and calcineurin regulates mitochondrial fission and cell 583
 death. EMBO Rep. 8, 939–944. 584
- Duncan, J.G., Fong, J.L., Medeiros, D.M., Finck, B.N., Kelly, D.P., 2007. Insulin-resistant 585
 heart exhibits a mitochondrial biogenic response driven by the peroxisome 586
 proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation 587
 115, 909–917. 588
- Feige, J.N., Auwerx, J., 2007. Transcriptional coregulators in the control of energy 589
 homeostasis. Trends Cell Biol. 17, 292–301. 590
- Feige, J.N., Auwerx, J., 2008. Transcriptional targets of sirtuins in the coordination of 591
 mammalian physiology. Curr. Opin. Cell Biol. 20, 303–309. 592
- Feige, J.N., Lagouge, M., Canto, C., Strehle, A., Houten, S.M., Milne, J.C., Lambert, P.D., 593
 Matakis, C., Elliott, P.J., Auwerx, J., 2008. Specific SIRT1 activation mimics low energy 594
 levels and protects against diet-induced metabolic disorders by enhancing fat 595
 oxidation. Cell Metab. 8, 347–358. 596
- Finck, B.N., Kelly, D.P., 2007. Peroxisome proliferator-activated receptor gamma 597
 coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. 598
 Circulation 115, 2540–2548. 599
- Frazier, W.A., Gao, A.-G., Dimitry, J., Chung, J., Lindberg, F.P., Brown, E.J., Linder, M.E., 600
 1999. The thrombospondin receptor integrin-associated protein (CD47) functionally 601
 couples to heterotrimeric Gi. J. Biol. Chem. 274, 8554–8560. 602
- Guarente, L., 2008. Mitochondria—a nexus for aging, calorie restriction, and sirtuins? 603
 Cell 132, 171–176. 604
- Holloszy, J.O., 2008. Regulation by exercise of skeletal muscle content of mitochondria 605
 and GLUT4. J. Physiol. Pharmacol. 59 (Suppl. 7), 5–18. 606
- Isenberg, J.S., Calzada, M.J., Zhou, L., Guo, N., Lawler, J., Wang, X.Q., Frazier, W.A., 607
 Roberts, D.D., 2005. Endogenous thrombospondin-1 is not necessary for proliferation 608
 but is permissive for vascular smooth muscle cell responses to platelet- 609
 derived growth factor. Matrix Biol. 24, 110–123. 610
- Isenberg, J.S., Ridnour, L.A., Dimitry, J., Frazier, W.A., Wink, D.A., Roberts, D.D., 2006a. 611
 CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses 612
 by thrombospondin-1. J. Biol. Chem. 281, 26069–26080. 613
- Isenberg, J.S., Wink, D.A., Roberts, D.D., 2006b. Thrombospondin-1 antagonizes nitric 614
 oxide-stimulated vascular smooth muscle cell responses. Cardiovasc. Res. 71, 615
 785–793. 616
- Isenberg, J.S., Hyodo, F., Matsumoto, K., Romeo, M.J., Abu-Asab, M., Tsokos, M., 617
 Kuppasamy, P., Wink, D.A., Krishna, M.C., Roberts, D.D., 2007a. Thrombospondin-1 618
 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth 619
 muscle relaxation. Blood 109, 1945–1952. 620
- Isenberg, J.S., Hyodo, F., Pappan, L.K., Abu-Asab, M., Tsokos, M., Krishna, M.C., Frazier, W. 621
 A., Roberts, D.D., 2007b. Blocking thrombospondin-1/CD47 signaling alleviates 622
 deleterious effects of aging on tissue responses to ischemia. Arterioscler. Thromb. 623
 Vasc. Biol. 27, 2582–2588. 624
- Isenberg, J.S., Romeo, M.J., Abu-Asab, M., Tsokos, M., Oldenborg, A., Pappan, L., Wink, D. 625
 A., Frazier, W.A., Roberts, D.D., 2007c. Increasing survival of ischemic tissue by 626
 targeting CD47. Circ. Res. 100, 712–720. 627
- Isenberg, J.S., Frazier, W.A., Krishna, M.C., Wink, D.A., Roberts, D.D., 2008a. Enhancing 628
 cardiovascular dynamics by inhibition of thrombospondin-1/CD47 signaling. Curr. 629
 Drug Targets 9, 833–841. 630

- 631 Isenberg, J.S., Frazier, W.A., Roberts, D.D., 2008b. Thrombospondins: from structure to
632 therapeutics: thrombospondin-1: a physiological regulator of nitric oxide signal-
633 ing. *Cell. Mol. Life Sci.* 65, 728–742.
- 634 Isenberg, J.S., Maxhimer, J.B., Hyodo, F., Pendrak, M.L., Ridnour, L.A., DeGraff, W.G.,
635 Tsokos, M., Wink, D.A., Roberts, D.D., 2008c. Thrombospondin-1 and CD47 limit cell
636 and tissue survival of radiation injury. *Am. J. Pathol.* 173, 1100–1112.
- 637 Isenberg, J.S., Maxhimer, J.B., Powers, P., Tsokos, M., Frazier, W.A., Roberts, D.D., 2008d.
638 Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1/
639 CD47 signaling. *Surgery* 144, 752–761.
- 640 Isenberg, J.S., Pappan, L.K., Romeo, M.J., Abu-Asab, M., Tsokos, M., Wink, D.A., Frazier, W.
641 A., Roberts, D.D., 2008e. Blockade of thrombospondin-1-CD47 interactions prevents
642 necrosis of full thickness skin grafts. *Ann. Surg.* 247, 180–190.
- 643 Isenberg, J.S., Roberts, D.D., Frazier, W.A., 2008f. CD47: a new target in cardiovascular
644 therapy. *Arterioscler. Thromb. Vasc. Biol.* 28, 615–621.
- 645 Isenberg, J.S., Romeo, M.J., Yu, C., Yu, C.K., Nghiem, K., Monsale, J., Rick, M.E., Wink, D.A.,
646 Frazier, W.A., Roberts, D.D., 2008g. Thrombospondin-1 stimulates platelet
647 aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling.
648 *Blood* 111, 613–623.
- 649 Isenberg, J.S., Qin, Y., Maxhimer, J.B., Sipes, J.M., Despres, D., Schnermann, J., Frazier, W.
650 A., Roberts, D.D., 2009. Thrombospondin-1 and CD47 regulate blood pressure and
651 cardiac responses to vasoactive stress. *Matrix Biol.* 28, 110–119.
- 652 Jin, G., Tsuji, K., Xing, C., Yang, Y.G., Wang, X., Lo, E.H., 2009. CD47 gene knockout protects
653 against transient focal cerebral ischemia in mice. *Exp. Neurol.* 217, 165–170.
- 654 Katic, M., Kennedy, A.R., Leykin, I., Norris, A., McGettrick, A., Gesta, S., Russell, S.J.,
655 Blucher, M., Maratos-Flier, E., Kahn, C.R., 2007. Mitochondrial gene expression and
656 increased oxidative metabolism: role in increased lifespan of fat-specific insulin
657 receptor knock-out mice. *Aging Cell* 6, 827–839.
- 658 Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F.,
659 Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al., 2006. Resveratrol improves
660 mitochondrial function and protects against metabolic disease by activating SIRT1
661 and PGC-1 α . *Cell* 127, 1109–1122.
- 662 Lai, L., Leone, T.C., Zechner, C., Schaeffer, P.J., Kelly, S.M., Flanagan, D.P., Medeiros, D.M.,
663 Kovacs, A., Kelly, D.P., 2008. Transcriptional coactivators PGC-1 α and PGC-1 β control
664 overlapping programs required for perinatal maturation of the heart. *Genes*
665 *Dev.* 22, 1948–1961.
- 666 Le Gouill, E., Jimenez, M., Binnert, C., Jayet, P.Y., Thalman, S., Nicod, P., Scherrer, U.,
667 Vollenweider, P., 2007. Endothelial nitric oxide synthase (eNOS) knockout mice
668 have defective mitochondrial beta-oxidation. *Diabetes* 56, 2690–2696.
- 669 Leone, T.C., Lehman, J.J., Finck, B.N., Schaeffer, P.J., Wende, A.R., Boudina, S., Courtois, M.,
670 Wozniak, D.F., Sambandam, N., Bernal-Mizrachi, C., et al., 2005. PGC-1 α deficiency
671 causes multi-system energy metabolic derangements: muscle dysfunction,
672 abnormal weight control and hepatic steatosis. *PLoS Biol.* 3, e101.
- 673 Lin, J., Wu, H., Tarr, P.T., Zhang, C.Y., Wu, Z., Boss, O., Michael, L.F., Puigserver, P., Isotani,
674 E., Olson, E.N., et al., 2002. Transcriptional co-activator PGC-1 α drives the
675 formation of slow-twitch muscle fibres. *Nature* 418, 797–801.
- 676 Lin, J., Handschin, C., Spiegelman, B.M., 2005. Metabolic control through the PGC-1
677 family of transcription coactivators. *Cell Metab.* 1, 361–370.
- 678 Lindberg, F.P., Bullard, D.C., Caver, T.E., Gresham, H.D., Beaudet, A.L., Brown, E.J., 1996.
679 Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient
680 mice. *Science* 274, 795–798.
- 681 Lira, V.A., Benton, C.R., Yan, Z., and Bonen, A. PGC-1 α regulation by exercise training
682 and its influences on muscle function and insulin sensitivity. *Am. J. Physiol.*
683 *Endocrinol. Metab.* 299, E145–161.
- 684 Lira, V.A., Brown, D.L., Lira, A.K., Kavazis, A.N., Soltow, Q.A., Zeanah, E.H., and Criswell, D.
685 S. Nitric oxide and AMPK cooperatively regulate PGC-1 in skeletal muscle cells. *J.*
686 *Physiol.* 588, 3551–3566.
- 687 Lopez-Lluch, G., Hunt, N., Jones, B., Zhu, M., Jamieson, H., Hilmer, S., Cascajo, M.V., Allard,
688 J., Ingram, D.K., Navas, P., et al., 2006. Calorie restriction induces mitochondrial
689 biogenesis and bioenergetic efficiency. *Proc. Natl Acad. Sci. USA* 103, 1768–1773.
- 690 Malek, M.H., Olfert, I.M., 2009. Global deletion of thrombospondin-1 increases cardiac and
691 skeletal muscle capillarity and exercise capacity in mice. *Exp. Physiol.* 94, 749–760.
- 692 Manna, P.P., Frazier, W.A., 2003. The mechanism of CD47-dependent killing of T cells:
693 heterotrimeric Gi-dependent inhibition of protein kinase A. *J. Immunol.* 170,
694 3544–3553.
- 695 Maxhimer, J.B., Shih, H.B., Isenberg, J.S., Miller, T.W., Roberts, D.D., 2009. Thrombos-
696 pondin-1/CD47 blockade following ischemia-reperfusion injury is tissue protec-
697 tive. *Plast. Reconstr. Surg.* 124, 1880–1889.
- 698 Miller, T.W., Isenberg, J.S., and Roberts, D.D. Thrombospondin-1 is an inhibitor of
699 pharmacological activation of soluble guanylate cyclase. *Br. J. Pharmacol.* 159,
700 1542–1547.
- 701 Nemoto, S., Fergusson, M.M., Finkel, T., 2005. SIRT1 functionally interacts with the
702 metabolic regulator and transcriptional coactivator PGC-1 α . *J. Biol. Chem.*
703 280, 16456–16460.
- 704 Nisoli, E., Carruba, M.O., 2006. Nitric oxide and mitochondrial biogenesis. *J. Cell Sci.* 119,
705 2855–2862.
- 706 Nisoli, E., Falcone, S., Tonello, C., Cozzi, V., Palomba, L., Fiorani, M., Pisconti, A., Brunelli,
707 S., Cardile, A., Francolini, M., et al., 2004. Mitochondrial biogenesis by NO yields
708 functionally active mitochondria in mammals. *Proc. Natl Acad. Sci. USA* 101,
709 16507–16512.
- 710 Oh, M., Rybkin, I.L., Copeland, V., Czubryt, M.P., Shelton, J.M., van Rooij, E., Richardson, J.
711 A., Hill, J.A., De Windt, L.J., Bassel-Duby, R., et al., 2005. Calcineurin is necessary for
712 the maintenance but not embryonic development of slow muscle fibers. *Mol. Cell.*
713 *Biol.* 25, 6629–6638.
- 714 Rodgers, J.T., Lerin, C., Haas, W., Gygi, S.P., Spiegelman, B.M., Puigserver, P., 2005.
715 Nutrient control of glucose homeostasis through a complex of PGC-1 α and
716 SIRT1. *Nature* 434, 113–118.
- 717 Salminen, A., Kaarniranta, K., 2009. SIRT1: regulation of longevity via autophagy. *Cell.*
718 *Signal.* 21, 1356–1360.
- 719 Scherz-Shouval, R., Elazar, Z., 2007. ROS, mitochondria and the regulation of autophagy.
720 *Trends Cell Biol.* 17, 422–427.
- 721 Scherz-Shouval, R., Shvets, E., Fass, E., Shorer, H., Gil, L., Elazar, Z., 2007. Reactive oxygen
722 species are essential for autophagy and specifically regulate the activity of Atg4.
723 *EMBO J.* 26, 1749–1760.
- 724 Schmidt, R.E., Green, K.G., Snipes, L.L., Feng, D., 2009. Neuritic dystrophy and
725 neuronopathy in Akita (Ins2(Akita)) diabetic mouse sympathetic ganglia. *Exp.*
726 *Neurol.* 216, 207–218.
- 727 Shiva, S., Sack, M.N., Greer, J.J., Duranski, M., Ringwood, L.A., Burwell, L., Wang, X.,
728 MacArthur, P.H., Shojia, A., Raghavachari, N., et al., 2007. Nitrite augments tolerance
729 to ischemia/reperfusion injury via the modulation of mitochondrial electron
730 transfer. *J. Exp. Med.* 204, 2089–2102.
- 731 Spangenburg, E.E., Booth, F.W., 2003. Molecular regulation of individual skeletal muscle
732 fibre types. *Acta Physiol. Scand.* 178, 413–424.
- 733 Timmers, H.J., Pacak, K., Huynh, T.T., Abu-Asab, M., Tsokos, M., Merino, M.J., Baysal, B.E.,
734 Adams, K.T., Eisenhofer, G., 2008. Biochemically silent abdominal paragangliomas
735 in patients with mutations in the succinate dehydrogenase subunit B gene. *J. Clin.*
736 *Endocrinol. Metab.* 93, 4826–4832.
- 737 Uldry, M., Yang, W., St-Pierre, J., Lin, J., Seale, P., Spiegelman, B.M., 2006. Complementary
738 action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat
739 differentiation. *Cell Metab.* 3, 333–341.
- 740 Uluckan, O., Becker, S.N., Deng, H., Zou, W., Prior, J.L., Pivnicka-Worms, D., Frazier, W.A.,
741 Weilbaecher, K.N., 2009. CD47 regulates bone mass and tumor metastasis to bone.
742 *Cancer Res.* 69, 3196–3204.
- 743 Wang, X.Q., Lindberg, F.P., Frazier, W.A., 1999. Integrin-associated protein stimulates
744 alpha2beta1-dependent chemotaxis via Gi-mediated inhibition of adenylate
745 cyclase and extracellular-regulated kinases. *J. Cell Biol.* 147, 389–400.
- 746 Wenz, T., Rossi, S.G., Rotundo, R.L., Spiegelman, B.M., Moraes, C.T., 2009. Increased
747 muscle PGC-1 α expression protects from sarcopenia and metabolic disease
748 during aging. *Proc. Natl Acad. Sci. USA* 106, 20405–20410.
- 749 Wozniak, A.C., Anderson, J.E., 2007. Nitric oxide-dependence of satellite stem cell
750 activation and quiescence on normal skeletal muscle fibers. *Dev. Dyn.* 236,
751 240–250.
- 752 Wu, Z., Huang, X., Feng, Y., Handschin, C., Feng, Y., Gullicksen, P.S., Bare, O., Labow, M.,
753 Spiegelman, B., Stevenson, S.C., 2006. Transducer of regulated CREB-binding
754 proteins (TORCs) induce PGC-1 α transcription and mitochondrial biogenesis in
755 muscle cells. *Proc. Natl Acad. Sci. USA* 103, 14379–14384.
- 756 Yao, M., Roberts, D.D., and Isenberg, J.S., in press. Thrombospondin-1 inhibition of
757 vascular smooth muscle cell responses occurs via modulation of both cAMP and
758 cGMP. *Pharmacol. Res.*